Flurbiprofen pretreatment in argon laser trabeculoplasty for primary open-angle glaucoma
R. N. Weinreb, A. L. Robin, G. Baerveldt, M. V. Drake, M. Blumenthal and J. Wilensky
We examined the influence of topically administered flurbiprofen sodium
0.03%, a potent prostaglandin inhibitor, on the inflammatory response and
intraocular pressure following argon laser trabeculoplasty. Our
investigation included one eye of each of 118 patients with primary
open-angle glaucoma in whom laser trabeculoplasty was indicated.
Sixty-three patients received flurbiprofen and 55 received a vehicle during
the two-hour period immediately preceding laser therapy and for one week
postoperatively. No significant differences in postoperative IOPs were
noted between groups. However, when we considered conjunctival erythema at
24 hours or control of inflammation at the termination of the
investigation, the eyes receiving flurbiprofen had less inflammation than
did the vehicle-treated eyes.
